Salt Lake City, UT, United States of America

Wei Li

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: University of Utah Research Foundation. Active years: 2015.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Wei Li - Innovator in Therapeutic Applications

Introduction

Wei Li is a prominent inventor based in Salt Lake City, UT (US). He has made significant contributions to the field of therapeutic applications, particularly in the development of compounds that can be used in the prevention and treatment of serious health conditions such as cancer and Alzheimer's disease.

Latest Patents

Wei Li holds a patent for "Bryostatin analogues and methods of making and using thereof." This patent describes tricyclic macrolactones that exhibit a high binding affinity for Protein Kinase C (PKC). The compounds outlined in this patent have potential applications in treating memory loss and can be utilized in various therapeutic contexts, including cancer and Alzheimer's prevention and treatment. Additionally, the patent details methods for producing these macrolactones, allowing for high-yield synthesis in fewer steps with greater specificity.

Career Highlights

Wei Li is affiliated with the University of Utah Research Foundation, where he continues to advance his research and innovation in the field of therapeutic compounds. His work is characterized by a commitment to improving health outcomes through scientific discovery.

Collaborations

Wei Li has collaborated with notable colleagues, including Gary E. Keck and Matthew B. Kraft, who have contributed to his research endeavors.

Conclusion

Wei Li's innovative work in developing Bryostatin analogues showcases his dedication to addressing critical health challenges. His contributions to therapeutic applications highlight the importance of research in improving patient care and treatment options.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…